BioMedNewsBreaks

TuesdayMay 04, 2021 4:22 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Proven Pharmaceutical Exec as Chief Commercial Officer

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Ann Cunningham as its chief commercial officer. Cunningham, who has been and will continue serving on VTGN’s board of directors, has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing and global life cycle product management expertise in roles across several health care markets, including neuropsychiatry and other CNS markets that VistaGen is pursuing. “Since joining our board, Ann’s…

Continue Reading

TuesdayMay 04, 2021 12:19 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). An open-label, multicenter Phase 1/2 clinical trial, Acclaim-2 combines Genprex’s lead drug candidate, REQORSA(TM) immunogene therapy, with Merck & Co Inc.’s Keytruda in patients with late-stage NSCLC who are low expressors (1% to 49%) of the protein programmed death-ligand 1 ("PD-L1"). “Our clinical team remains focused on engaging with leading clinical investigators and esteemed research institutions in…

Continue Reading

MondayMay 03, 2021 3:21 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Significant Market Opportunity

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, raised eyebrows when it announced that XPhyto Laboratories Inc., its Alberta subsidiary, added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/cHwJi). Mescaline has begun attracting legislative attention, much like was the case with cannabis, which gained widening legalization as state after state approved varied uses of hemp and cannabis within their political boundaries. Recently, California Senator Scott Wiener introduced a bill that would decriminalize select hallucinogenics, including mescaline, in part due to research from top medical universities indicating that such substances can have significant benefits…

Continue Reading

MondayMay 03, 2021 10:07 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered a master service agreement with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. The partnership will provide design and training for the psychotherapeutic component of Tryp's clinical trial activities and will strengthen Tryp's capability to plan and implement clinical trials. The agreement will also enhance the company’s ability to make the most of the information gathered. Fluence has specific expertise in psychedelic clinical trials…

Continue Reading

FridayApr 30, 2021 12:10 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Offering Cost-Effective, Efficient BCI Solutions

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, has created two FDA-cleared products (the NeuroCap(TM) and NeuroEEG(TM)) that are nothing like other brain-computer interface (“BCI”) solutions in the market. It has been observed that “data collected from consumer-centric, low-cost BCIs are typically not as efficient or as pristine as that retrieved from research-grade conventional wired EEGs (electroencephalograms),” notes a recent article. “Many of the BCIs on the market are not gelled so that the consumer can easily fit the product themselves. They have far fewer electrodes and are designed for the ease of the…

Continue Reading

ThursdayApr 29, 2021 2:01 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Continues to Strengthen Position in Plant-Based Health Industry

Healthy Extracts (OTCQB: HYEX) is committed to growth and has aligned its operations to focus on the plant-based health industry. Reflecting this focus, HYEX changed its name from Grey Cloak Tech to align with the company’s objectives and a “Live Life Young Again” strategy. “The company is making remarkable strides to strengthen its market positions in the plant-based health industry through its two key subsidiaries, the science-based BergaMet North America and Ultimate Brain Nutrients (‘UBN’),” reads a recent article. The company also achieved significant accomplishments in 2020, including a 71% increase in recorded gross revenue, despite the COVID pandemic, as…

Continue Reading

ThursdayApr 29, 2021 1:45 pm

BioMedNewsBreaks – RYAH Group Inc. Featured in Bell2Bell Podcast

RYAH Group, engaged in the development and commercialization of various innovative technology solutions for the plant-based medical industry, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. RYAH’s CEO Gregory Wagner joined the latest episode to discuss the company’s 2021 goals and milestones, as well as provide an overview of RYAH’s business model and product offerings. “I came to the company two years ago, and the reason why I came here from a different career was because I was completely floored by the amount of data this…

Continue Reading

WednesdayApr 28, 2021 10:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Pursues Market Access in Israel for ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that it has delivered 2,000 of its rapid 25-minute PCR tests ("Covid-ID Lab") to an established medical distributor in Israel for clinical evaluation of Covid-ID Lab for the purpose of commercial regulatory approval and potential product distribution. According to the update, the Israeli distributor markets and distributes a range of medical products and diagnostics in Israel and surrounding Middle Eastern countries. Its customers include government and private institutions such as hospitals, pharmacies and a broad range of health care providers. "We are excited by the opportunity to expand potential distribution…

Continue Reading

WednesdayApr 28, 2021 9:36 am

BioMedNewsBreaks – RYAH Group Inc. to Begin Trading on CSE under RYAH Ticker

RYAH Group (formerly known as Prime Blockchain Inc.) has announced that, beginning Tuesday, May 4, its common shares will begin trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol RYAH. In accordance with CSE policies, the company has filed the required listing statement on SEDAR. RYAH just recently closed a reverse takeover transaction of Potbotics Inc., consisting of a triangular merger between the company (formerly Prime Blockchain, Inc.), Potbotics and a wholly owned Florida subsidiary of the company. “This is another major step in our journey in transforming patient care through our remote, connected devices and data analytics,…

Continue Reading

TuesdayApr 27, 2021 3:08 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Featured in DojoLIVE! Interview

Predictive Oncology’s (NASDAQ: POAI) subsidiary company, Helomics, was recently featured on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of industries. The company’s Chief Technical Officer, Mark Collins, PhD, joined the interview to discuss what Helomics is bringing to the table in the field of cancer research in the podcast titled “Can We Cure Cancer with Artificial Intelligence?” “At Helomics, we have a nice convergence of data that we’ve gathered from testing live tumors, tumors outside the patient body, on drugs, standard of care drugs, normal drugs that you…

Continue Reading